RION, a regenerative medicine company spun out from Mayo Clinic, has announced it’ll contract Lonza Bioscience to manufacture commercial production of RION’s Purified Exosome Product™ (PEP™).
PEP™ was discovered at the Mayo Clinic Van Cleve Cardiac Regenerative Medicine Program by RION scientists in 2017, after two decades of research into platelet-derived regenerative exosomes. It’s formulated as a shelf-stable lyophilized (freeze-dried) powder, which they report possesses immunomodulatory, anti-inflammatory, and tissue regenerative properties. Stabilized regenerative exosomes are designed to promote tissue repair and can be administered through multiple routes, potentially supporting use across a broad set of indications, including immune-mediated dermatology diseases, musculoskeletal disease, pulmonary disease, cardiovascular health, and women’s health.
Under the agreement, Lonza will manufacture PEP™ at its Houston facility, leveraging its expertise in extracellular vesicle development and manufacturing to help operationalize RION’s process at scale.
Atta Behfar, Cofounder and CEO of RION said: “This collaboration with Lonza ensures that our proprietary exosome manufacturing platform can be scaled to meet clinical and future commercial demand. RION’s breakthrough in exosome biomanufacturing, now paired with Lonza’s global infrastructure, allows us to bring this biologics-based innovation to patients rapidly and reliably, while staying true to our mission of affordable access.”
For more information about Lonza’s exosome manufacturing, check out this link.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
